All Stories

  1. Fatty acid abnormalities in cystic fibrosis –the missing link for a cure?
  2. Serum phospholipid fatty acids are associated with bone mass in healthy 4-years-old children.
  3. Elevated plasma phospholipid n-3 docosapentaenoic acid concentrations during hibernation
  4. The fatty acid imbalance of cystic fibrosis exists at birth independent of feeding in pig and ferret models
  5. Geographical distribution of cystic fibrosis carriers as population genetic determinant of COVID-19 spread and fatality in 37 countries
  6. Omega-3 fatty acids decrease CRYAB, production of oncogenic prostaglandin E2 and suppress tumor growth in medulloblastoma
  7. Ursodeoxycholic acid and liver disease associated with cystic fibrosis: A multicenter cohort study
  8. Nutrition in Cystic Fibrosis—Some Notes on the Fat Recommendations
  9. Liver X receptor β regulates bile volume and the expression of aquaporins and cystic fibrosis transmembrane conductance regulator in the gallbladder
  10. Body surface area-based omega-3 fatty acids supplementation strongly correlates to blood concentrations in children.
  11. Is the ENaC Dysregulation in CF an Effect of Protein-Lipid Interaction in the Membranes?
  12. P059 A double-blind randomised multi-centre European study of linoleic acid supplementation for one year in patients with cystic fibrosis
  13. Abnormal n-6 fatty acid metabolism in cystic fibrosis contributes to pulmonary symptoms
  14. Chapter 2. ESPGHAN: 50 Years Memories—The Early Years
  15. Chapter 8. 50 Years of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN): Captivating Witness Reports of a Success Story
  16. Low linoleic and high docosahexaenoic acids in a severe phenotype of transgenic cystic fibrosis mice
  17. Serum n-6 and n-9 Fatty Acids Correlate With Serum IGF-1 and Growth Up to 4 Months of Age in Healthy Infants
  18. 304 Severe phenotype of CF mice with low linoleic acid and high docosahexaenoic acid concentrations in serum phospholipids
  19. Highlights of the ESPEN-ESPGHAN-ECFS Guidelines on Nutrition Care for Infants and Children With Cystic Fibrosis
  20. ESPEN-ESPGHAN-ECFS guidelines on nutrition care for infants, children, and adults with cystic fibrosis
  21. Long-chain saturated and monounsaturated fatty acids associate with development of premature infants up to 18 months of age
  22. Antinociceptive fatty acid patterns differ in children with psychosomatic recurrent abdominal pain and healthy controls
  23. The development of infants born to obese mothers might be related to omega-3 fatty acid status
  24. Perinatal programming by diets with essential fatty acid deficient/high saturated fatty acids or different n-6/n-3 ratios for diseases in adulthood
  25. Lipid Quality in Infant Nutrition
  26. Can Lipidomics Conceal the Key for Understanding Celiac Disease?
  27. Dietary Fat and Fat Metabolism in CF
  28. Essential Fatty Acid Deficiency in Cystic Fibrosis
  29. IL-1β expression in the distal lung epithelium disrupts lung morphogenesis and epithelial cell differentiation in fetal mice
  30. Omega-6 and omega-3 fatty acids in milk and beneficial impact on the infant
  31. Nervonic acid is much lower in donor milk than in milk from mothers delivering premature infants—Of neglected importance?
  32. Polyamine levels in breast milk are associated with mothers' dietary intake and are higher in preterm than full-term human milk and formulas
  33. Lower polyamine levels in breast milk of obese mothers compared to mothers with normal body weight
  34. Different fatty acid pattern in breast milk of obese compared to normal-weight mothers
  35. Relation Between Dietary Fat Intake Type and Serum Fatty Acid Status in Children With Cystic Fibrosis
  36. 243 IMPACT OF CHILDHOOD SOCIOECONOMIC STATUS ON SERUM LEVEL OF OMEGA-3 FATTY ACIDS AND CARDIOVASCULAR RISK FACTORS IN HEALTHY ADOLESCENTS. A 3-YEAR FOLLOW-UP STUDY
  37. Reasons given by mothers for discontinuing breastfeeding in Iran
  38. Motor, mental and behavioral developments in infancy are associated with fatty acid pattern in breast milk and plasma of premature infants
  39. High Physiological Omega-3 Fatty Acid Supplementation Affects Muscle Fatty Acid Composition and Glucose and Insulin Homeostasis in Obese Adolescents
  40. Response to the letter by Ooi et al.
  41. The omega-6/omega-3 ratio is of importance!
  42. Early behavior and development are influenced by the n-6 and n-3 status in prematures
  43. Postnatal essential fatty acid deficiency in mice affects lipoproteins, hepatic lipids, fatty acids and mRNA expression
  44. Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease
  45. New clinical diagnostic procedures for cystic fibrosis in Europe
  46. Prenatal essential fatty acid deficiency in mice results in long-term gender-specific effects on body weight and glucose metabolism
  47. Noncirrhotic presinusoidal portal hypertension is common in cystic fibrosis-associated liver disease
  48. Postnatal deficiency of essential fatty acids in mice results in resistance to diet-induced obesity and low plasma insulin during adulthood
  49. The skinny on tuna fat: health implications
  50. From the Swedish to the Mediterranean Diet and the Omega-6/Omega-3 Balance
  51. Optimal vitamin A and suboptimal vitamin D status are common in Iranian infants
  52. Omega-3 fatty acid supplementation improves vascular function and reduces inflammation in obese adolescents
  53. Inverse relation between vitamin D and serum total immunoglobulin G in the Scandinavian Cystic Fibrosis Nutritional Study
  54. Fatty acid metabolism in cystic fibrosis
  55. High levels of soluble intercellular adhesion molecule-1, insulin resistance and saturated fatty acids are associated with endothelial dysfunction in healthy adolescents
  56. Early behaviour and development in breast-fed premature infants are influenced by omega-6 and omega-3 fatty acid status
  57. Food choice is reflected in serum markers and anthropometric measures in healthy 8-yr-olds
  58. EPA supplementation improves teacher-rated behaviour and oppositional symptoms in children with ADHD
  59. Supplementation With Fatty Acids Influences the Airway Nitric Oxide and Inflammatory Markers in Patients With Cystic Fibrosis
  60. Fatty acid composition of diet, cord blood and breast milk in Chinese mothers with different dietary habits
  61. Metabolic profiles of fat and glucose differ by gender in healthy 8-year-olds
  62. Heart rate recovery in young adult patients with cystic fibrosis
  63. Processed animal products with emphasis on polyunsaturated fatty acid content
  64. Ezrin-Radixin-Moesin-Binding Phosphoprotein (EBP50), an Estrogen-Inducible Scaffold Protein, Contributes to Biliary Epithelial Cell Proliferation
  65. Fatty acid pattern in serum is associated with bone mineralisation in healthy 8-year-old children
  66. Breastfeeding in Iran: prevalence, duration and current recommendations
  67. Fatty acid patterns early after premature birth, simultaneously analysed in mothers' food, breast milk and serum phospholipids of mothers and infants
  68. Liver function and morphology during long-term fatty acid supplementation in cystic fibrosis
  69. Liver damage in juvenile inflammatory bowel disease
  70. Serum Linoleic Acid Status as a Clinical Indicator of Essential Fatty Acid Status in Children With Cystic Fibrosis
  71. Volumetric bone mineral density is an important tool when interpreting bone mineralization in healthy children
  72. SUPPLEMENT WITH OMEGA 3 FATTY ACIDS IMPROVES ENDOTHELIAL FUNCTION IN OBESE ADOLESCENTS
  73. Is the relatively low intake of omega‐3 fatty acids in Western diet contributing to the obesity epidemics?
  74. Muscular strength after different types of training in physically active patients with cystic fibrosis
  75. Cardiopulmonary Data in Response to 6 Months of Training in Physically Active Adult Patients with Classic Cystic Fibrosis
  76. Fatty acid composition in breast milk and serum phospholipids of healthy term Chinese infants during first 6 weeks of life
  77. Abstract 3646: Supplement with Omega-3 Fatty Acids Lowers Pulse Wave Velocity in Obese Adolescents
  78. Dornase alfa is well tolerated: Data from the Epidemiologic Registry of Cystic Fibrosis
  79. Docosahexaenoic acid is associated with endosteal circumference in long bones in young males with cystic fibrosis
  80. 235 Serum vitamin E and IL-6 are influenced by type of physical training in patients with CF
  81. Airway Nitric Oxide in Patients With Cystic Fibrosis Is Associated With Pancreatic Function, Pseudomonas Infection, and Polyunsaturated Fatty Acids
  82. Food choice, socio-economic characteristics and health in 4-year olds in a well-educated urban Swedish community
  83. Swedish pre-school children eat too much junk food and sucrose
  84. Ultraviolet B radiation improves serum levels of vitamin D in patients with cystic fibrosis
  85. Epithelial Electrical Resistance as a Measure of Permeability Changes in Pediatric Duodenal Biopsies
  86. Metabolic markers in relation to nutrition and growth in healthy 4-y-old children in Sweden
  87. Serum Phospholipid Fatty Acids, Adipose Tissue, and Metabolic Markers in Obese Adolescents*
  88. LINOLEIC ACID STATUS FOR THE DIAGNOSIS OF ESSENTIAL FATTY ACID DEFICIENCY IN CHILDREN WITH CYSTIC FIBROSIS
  89. Abnormal Fatty Acid Pattern in Intestinal Mucosa of Children With Celiac Disease Is Not Reflected in Serum Phospholipids
  90. Mediterranean diet and cystic fibrosis
  91. Serum phospholipid fatty acid pattern is associated with bone mineral density in children, but not adults, with cystic fibrosis
  92. 312 EBP50, a scaffold protein participating in the proliferation of cholangiocytes, is delocalized in the ductular reaction associated with cystic fibrosis liver disease
  93. Mediterranean-inspired diet lowers the ratio of serum phospholipid n–6 to n–3 fatty acids, the number of leukocytes and platelets, and vascular endothelial growth factor in healthy subjects
  94. Die Versorgung von Mukoviszidose-Patienten
  95. Care of Patients with Cystic Fibrosis
  96. Perinatal PUFA Intake Affects Leptin and Oral Tolerance in Neonatal Rats and Possibly Immunoreactivity in Intrauterine Growth Retardation in Man
  97. 212 Working capacity and lung function in physically active patients with Cystic Fibrosis were unchanged after 6 months of training
  98. 280 Serum phospholipid fatty acid pattern is associated with bone growth in children but not adults with Cystic Fibrosis
  99. Asistencia de pacientes con fibrosis quística
  100. Soins des patients atteints d’une mucoviscidose
  101. Trampolines are Useful in the Treatment of Cystic Fibrosis Patients
  102. ESSENTIAL FATTY ACID DEFICIENCY AND THE CLINICAL RELEVANCE OF THE TRIENE:TETRAENE RATIO IN CHILDREN WITH CYSTIC FIBROSIS
  103. Muscular Strength and Function in Patients With Cystic Fibrosis
  104. Cost-Effectiveness of Alendronate in the Prevention of Osteoporotic Fractures in Danish Women
  105. DISTURBED PHOSPHOLIPID FATTY ACID PATTERN IN INTESTINAL BIOPSIES FROM PATIENTS WITH COELIAC DISEASE
  106. MARKED CHANGES IN THE MRNA EXPRESSION OF PPARS IN THE LIVER OF MICE WITH PERINATAL ESSENTIAL FATTY ACID DEFICIENCY
  107. Gender-related long-term effects in adult rats by perinatal dietary ratio of n-6/n-3 fatty acids
  108. Cysteinyl leukotrienes are secretagogues in atrophic coeliac and in normal duodenal mucosa of children
  109. Perinatal essential fatty acid deficiency influences body weight and bone parameters in adult male rats
  110. Dietary n-6:n-3 fatty acid ratio in the perinatal period affects bone parameters in adult female rats
  111. The ratio of n-6 to n-3 fatty acids in maternal diet influences the induction of neonatal immunological tolerance to ovalbumin
  112. Normal Annual Increase of Bone Mineral Density During Two Years in Patients With Cystic Fibrosis
  113. Modulation of neonatal immunological tolerance to ovalbumin by maternal essential fatty acid intake
  114. Duodenogastric Bile Reflux Is Common in Cystic Fibrosis
  115. Severe Hypercholesterolaemia Leads to Strong Th2 Responses to an Exogenous Antigen
  116. Fatty Acid Metabolism in Cystic Fibrosis
  117. Association between serum oncofetal antigens CA 19-9 and CA 125 and clinical status in patients with cystic fibrosis
  118. Dornase alfa in the treatment of cystic fibrosis in Europe: A report from the Epidemiologic Registry of Cystic Fibrosis
  119. The Transfer of Immunity from Mother to Child
  120. Decreased bone mineral density in normal-growing patients with cystic fibrosis
  121. Leptin levels in rat offspring are modified by the ratio of linoleic to α-linolenic acid in the maternal diet
  122. Breast-feeding, a complex support system for the offspring
  123. Breast‐feeding, a complex support system for the offspring
  124. Maternal Dietary Intake of Essential Fatty Acids Affects Adipose Tissue Growth and Leptin mRNA Expression in Suckling Rat Pups
  125. Predictors of deterioration of lung function in cystic fibrosis*
  126. Electrogenic Ion Transport in Duodenal Biopsies from Children with Coeliac Disease
  127. Essential fatty acid deficiency in relation to genotype in patients with cystic fibrosis
  128. Presence of cystic fibrosis‐related diabetes mellitus is tightly linked to poor lung function in patients with cystic fibrosis: Data from the European Epidemiologic Registry of Cystic Fibrosis
  129. Water-miscible tocopherol is not superior to fat-soluble preparation for vitamin E absorption in cystic fibrosis
  130. Spectrum of Mutations in theCFTRGene of Patients with Classical and Atypical Forms of Cystic Fibrosis from Southwestern Sweden: Identification of 12 Novel Mutations
  131. Factors associated with poor pulmonary function: cross-sectional analysis of data from the ERCF
  132. Gastric IgA in Cystic Fibrosis in Relation to the Migrating Motor Complex
  133. Allergic bronchopulmonary aspergillosis in cystic fibrosis
  134. Maternal essential fatty acid deficiency depresses serum leptin levels in suckling rat pups
  135. Gastric Secretion in Cystic Fibrosis in Relation to the Migrating Motor Complex
  136. European Epidemiologic Registry of Cystic Fibrosis (ERCF): Comparison of major disease manifestations between patients with different classes of mutations
  137. Allergic bronchopulmonary aspergillosis in cystic fibrosis. A European epidemiological study
  138. Essential fatty acid deficiency affects the fatty acid composition of the rat small intestinal and colonic mucosa differently
  139. Diagnostic test meal in childhood enteropathy using simultaneous carbohydrate and fat loading
  140. Expression of cystic fibrosis transmembrane conductance regulator in liver tissue from patients with cystic fibrosis
  141. Characterization of a novel 21-kb deletion, CFTRdele2,3(21 kb), in the CFTR gene: a cystic fibrosis mutation of Slavic origin common in Central and East Europe
  142. Electrogenic Ion Transport in Duodenum, an Aid in Cystic Fibrosis Diagnosis
  143. Nutritional management in cystic fibrosis
  144. Natural history of liver disease in cystic fibrosis
  145. Composition and permeability of syncytiotrophoblast plasma membranes in pregnancies complicated by intrauterine growth restriction
  146. Allergy to laboratory animals in children of parents occupationally exposed to mice, rats and hamsters
  147. Therapeutic drug monitoring in patients with cystic fibrosis and mycobacterial disease
  148. 17. Eight new mutations identified at the West Swedish CF-center
  149. 65. Totally implantable venous access in patients with cystic fibrosis (CF)
  150. E2.1 Risk factors of importance for long-term survival of patients with cystic fibrosis
  151. E2.3 The European Epidemiological Registry of Cystic Fibrosis (ERCF). Does pulmozyme make any difference?
  152. CHLORIDE SECRETION IN DUODENUM, AN AID IN CYSTIC FIBROSIS (CF) DIAGNOSIS
  153. BILE ACID REGURGITATION INTO THE STOMACH IS A COMMON FINDING IN CYSTIC FIBROSIS (CF)
  154. GASTRIC IgA IN CYSTIC FIBROSIS (CF) IN RELATION TO MIGRATING MOTOR COMPLEXES (MMC)
  155. Multicenter, open-label study of recombinant human DNase in cystic fibrosis patients with moderate lung disease
  156. RAT SERUM ARCHIDONIC ACID DECLINES DURING THE LACTATION PERIOD
  157. ESSENTIAL FATTY ACID DEFICIENCY DIFFERENTLY AFFECTS THE FATTY ACID COMPOSITION OF THE RAT INTESTINAL AND COLONIC MUCOSA.
  158. PROSPECTIVE STUDY OF LIVER DISEASE FOR 15 YEARS IN CYSTIC FIBROSIS (CF)
  159. URINARY BILE ACID EXCTRETION PATTERN IN CHILDREN WITH AAGENAES SYNDROME
  160. A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease
  161. Intestinal Permeability in Cystic Fibrosis in Relation to Genotype
  162. Reply to Angelico
  163. EFFECTS OF ARACHIDONIC ACID METABOLITES ON RECTAL ION TRANSPORT IN ULCERATIVE COLITIS
  164. Vitamin A Concentration in the Liver Decreases with Age in Patients with Cystic Fibrosis
  165. Electrogenic Ion Transport along the Human Duodenum in Childhood
  166. Prostanoid biosynthesis in patients with cystic fibrosis
  167. Bile acid kinetics and biliary lipid composition in cystic fibrosis
  168. Cystic Fibrosis Pulmonary Infection: The Swedish Experience
  169. Metabolism of orally fed [3H]-eicosapentaenoic and [14C]-arachidonic acid in essential fatty acid-deficient rats
  170. Leukotriene B4 and C4 Metabolism in Small Intestine Mucosa of Children with Celiac Disease
  171. Leukotriene B4and C4generation by human leukocytes after ex vivo stimulation with Ca-ionophore and opsonized zymosan in children with atopic asthma
  172. 51 INTESTINAL PERMEABILITY IN CYSTIC FIBROSIS (CF) IN RELATION TO GENOTYPE AND ESSENTIAL FATTY ACID DEFICIENCY (EFAD)
  173. 52 ESSENTIAL FATTY ACID DEFICIENCY (EFAD) IN RELATION TO GENOTYPE IN CYSTIC FIBROSIS (CF)
  174. Incidence of liver disease in patients with cystic fibrosis and meconium ileus
  175. Defective inhibition by dexamethasone of leukotriene B4 and C4 production by leukocytes in patients with cystic fibrosis
  176. 73 ELECTROGENIC ION TRANSPORT IN HUMAN DUODENUM
  177. 74 EFFECTS OF LEUKOTRIENES ON ION TRANSPORT IN HUMAN DUODENUM
  178. Inhibitory effects of theophylline, terbutaline, and hydrocortisone on leukotriene B4 and C4 generation by human leukocytes in vitro
  179. Bacterial colonisation withXanthomonas maltophilia — A retrospective study in a cystic fibrosis patient population
  180. Leukotriene B4and C4generation by blood leukocytes after ex vivo stimulation by Ca-ionophore and opsonized zymosan in children with atopic dermatitis
  181. Bile salt sulphotransferase activity in the liver of cholestatic infants
  182. High doses of aminoglycosides did not produce liver toxicity in patients with cystic fibrosis
  183. The urinary bile acid excretion in healthy premature and full-term infants during the neonatal period
  184. Effects of Different Formula Feeds on the Developmental Pattern of Urinary Bile Acid Excretion in Infants
  185. Effects of Pancreatic and Snake Venom Phospholipase A2 on the Generation of Leukotriene B4 and C4 by Human Leukocytes in Vitro
  186. Cystic Fibrosis Is Treatment with Ursodeoxycholic Acid of Value?
  187. Leukotriene B<sub>4</sub> and C<sub>4</sub> Generation by Small Intestinal Mucosa in Children with Coeliac Disease
  188. Leukotriene B4 generation by blood polymorphonuclear leukocytes after incubation in urine
  189. Immunoglobulin G antibodies toPseudomonas aeruginosa lipopolysaccharides and exotoxin A in patients with cystic fibrosis or bacteremia
  190. Frequency of four cystic fibrosis mutations in a Swedish population
  191. Nephrolithiasis in cystic fibrosis
  192. Leukotriene B4 and C4 Generation by Human Colostral Macrophages in vitro
  193. Increased oral bioavailability of ciprofloxacin in cystic fibrosis patients.
  194. Capacity of Small Intestinal Mucosa to Produce Leukotriene B4 and C4 in Children with Celiac Disease
  195. 6 ACCUMULATION OF IRON IN LIVERS FROM RATS DEFICIENT IN ESSENTIAL FATTY ACIDS (EFA);
  196. 73 LEUKOTRIENE B4 and C4 GENERATION IN SMALL INTESTINAL MUCOSA OF CHILDREN WITH COELIAC DISEASE
  197. Incorporation of dietary [14C]arachidonic acid and [3H]eicosapentaenoic acid into tissue lipids during absorption of a fish oil emulsion.
  198. Bile-duct destruction and collagen deposition: A prominent ultrastructural feature of the liver in cystic fibrosis
  199. The effect of essential fatty acid deficiency on hepatic bile salt sulphotransferase in rats
  200. Erythrocyte Sodium-Potassium Transport in Cystic Fibrosis
  201. Serum Primary Bile Acids in the Course of Celiac Disease in Children
  202. Craniofacial morphology in children with cystic fibrosis
  203. Home intravenous antibiotic treatment of patients with cystic fibrosis
  204. Long-term double-blind study on the influence of dietary fibres on faecal bile acid excretion in juvenile ulcerative colitis
  205. Liver Transplantation in a Boy with Acute Porphyria Due to Aminolaevulinate Dehydratase Deficiency
  206. The fertility potential of male cystic fibrosis patients
  207. Faecal bile acid excretion in children with inflammatory bowel disease.
  208. ABSORPTION AND METABOLISM OF 3H-EICOSAPENTAENOIC (EPA) AND 14C-ARACHIDONIC (AA) ACIDS IN NORMAL AND ESSENTIAL FATTY ACID (EFA) DEFICIENT RATS
  209. A simplified analysis of fatty acids in serum phospholipids using Sep-Pak cartridges
  210. Decreased Renal Clearance of Sodium in Cystic Fibrosis
  211. Serum Bile Acids in Relation to Disease Activity and Intake of Dietary Fibers in Juvenile Ulcerative Colitis
  212. Adaptive regulation of lipoprotein lipase and salt-resistant lipase activities in essential fatty acid deficiency: An experimental study in the rat
  213. Renal Function in Rats with Essential Fatty Acid Deficiency
  214. Pancreatic function in the essential fatty acid deficient rat
  215. Absorption and metabolism of [3H]arachidonic and [14C]linoleic acid in essential fatty acid-deficient rats
  216. Passive smoking in cystic fibrosis
  217. Metabolism of [3H]arachidonic acid- and [14C]linoleic acid-labelled chylomicrons in essential fatty acid-deficient rats
  218. Prospective study of mycobacterial infections in patients with cystic fibrosis.
  219. Antistaphylococcal antibodies in cystic fibrosis
  220. Phenobarbital Can Aggravate a Cholestatic Bile Acid Pattern in Infants with Obstructive Cholangiopathy
  221. Increased Renal Clearance of Cefsulodin Due to Higher Glomerular Filtration Rate in Cystic Fibrosis
  222. Ketonic bile acids in urine of infants during the neonatal period.
  223. Relation between Essential Fatty Acid Metabolism and Gastrointestinal Symptoms in Cystic Fibrosis
  224. PANCREATIC FUNCTION IN ESSENTIAL FATTY ACID DEFICIENT (EFAD) RATS
  225. Effect on renal function of essential fatty acid supplementation in cystic fibrosis
  226. Na, K-ATPase Activity in Rectal Mucosa of Children with Ulcerative Colitis and Crohn's Disease
  227. Serum and sputum concentrations of netilmicin in combination with acylureidopenicillin and cephalosporins in clinical treatment of pulmonary exacerbations in cystic fibrosis
  228. Increased bronchial chloride concentration in cystic fibrosis
  229. Increased nonrenal clearance and increased diuretic efficiency of furosemide in cystic fibrosis
  230. 93 FECAL BILE ACID (BA) EXCRETION IN CHILDREN WITH INFLAMMATORYDISEASE (IBD)
  231. 96 ABSORPTION AND LIVER UPTAKE OF 3H-ARACHIDONIC ACID AND C-LINOLEIC ACID IN ESSENTIAL FATTY ACID DEFICIENT (EFAD) RATS
  232. 95 ARACHIDONIC ACID RELEASE AND ESSENTIAL FATTY ACID DEFICIENCY IN CYSTIC FIBROSIS
  233. 77 PHENOBARBITAL (P) INCREASES CHOLESTASIS IN LIVER DISEASE – A HAZARD TO INFANTS?
  234. Discussion
  235. Composition and surface properties of the bronchial lipids in adult patients with cystic fibrosis
  236. DEFECTIVE BILE ACID AMIDATION: PREDICTED FEATURES OF A NEW INBORN ERROR OF METABOLISM
  237. Antibiotic Therapy of Pulmonary Infections in Cystic Fibrosis
  238. Antibiotic therapy of pulmonary infections in cystic fibrosis. Dosage schedules and duration of treatment
  239. Influence of the Glomerular Filtration Rate on Renal Clearance of Ceftazidime in Cystic Fibrosis
  240. 3-OXO-Δ4 BILE ACIDS IN LIVER DISEASE
  241. HAEMORRHAGIC PANCREATITIS AFTER ERCP IN PATIENTS WITH ALPHA1-ANTITRYPSIN DEFICIENCY
  242. Reply
  243. Imipenem/cilastatin, an alternative treatment of pseudomonas infection in cystic fibrosis
  244. Food Intake in Patients with Cystic Fibrosis on an Ordinary Diet
  245. Home Intravenous Antibiotic Treatment in Cystic Fibrosis
  246. Relation between Defective Regulation of Arachidonic Acid Release and Symptoms in Cystic Fibrosis
  247. Sclerosing Cholangitis in Cystic Fibrosis
  248. Prospective study of serum antibodies to Pseudomonas aeruginosa exoproteins in cystic fibrosis
  249. Prospective study of serum staphylococcal antibodies in cystic fibrosis.
  250. Granulocyte elastase-α1-antiproteinase complex in cystic fibrosis: Sensitive plasma assay for monitoring pulmonary infections
  251. Relation between clinical and roentgenological scores and measures of lung function in cystic fibrosis, with special reference to pulmonary Xenon133 elimination
  252. 2. SCLEROSING CHOLANGITIS IN CYSTIC FIBROSIS
  253. Psychosocial Stressors and Gastrointestinal Disorders in Childhood and Adolescense
  254. Pathological regulation of arachidonic acid release in cystic fibrosis: the putative basic defect.
  255. Morphological findings in the liver of children with cystic fibrosis: A light and electron microscopical study
  256. Absence of prostaglandins in semen of men with cystic fibrosis is an indication of the contribution of the seminal vesicles
  257. Conformity of bacterial growth in sputum and contamination free endobronchial samples in patients with cystic fibrosis.
  258. LIVER DAMAGE IN JUVENILE INFLAMMATORY BOWEL DISEASE
  259. Physical activity and self treatment in cystic fibrosis.
  260. Increased mole fraction of arachidonic acid in bronchial phospholipids in patients with cystic fibrosis
  261. Antibodies to Staphylococcal Teichoic Acid and Alpha Toxin in Patients with Cystic Fibrosis
  262. In vivo and vitro studies on formation of bile acids in patients with Zellweger syndrome. Evidence that peroxisomes are of importance in the normal biosynthesis of both cholic and chenodeoxycholic acid.
  263. Relation between antibody response to pseudomonas aeruginosa exoproteins and colonization/infection in patients with cystic fibrosis
  264. Nutritional status in children receiving home parenteral nutrition
  265. Unsuccessful Attempts to Induce Peroxisomes in Two Cases of Zellweger Disease by Treatment with Clofibrate
  266. 638 NUTRITION STATUS INF ED AND UNDFED CHILDREN RECEIVING HOME PARENTERAL
  267. Fasting Serum Bile Acid Levels in Relation to Liver Histopathology in Cystic Fibrosis
  268. Relation between Antibody Response to Pseudomonas aeruginosa Exoproteins and Colonization/Infection in Patients with Cystic Fibrosis
  269. Urinary excretion of dicarboxylic acids from patients with the zellweger syndrome Importance of peroxisomes in β-oxidation of dicarboxylic acids
  270. Persistent Tyrosinemia Associated with Low Activity of Tyrosine Aminotransferase
  271. ADVERSE REACTIONS TO PIPERACILLIN IN PATIENTS WITH CYSTIC FIBROSIS
  272. Urinary excretion of tetrahydroxylated bile acids in children with α1-antitrypsin deficiency and neonatal cholestasis
  273. Prospective Study of Fatty Acid Supplementation Over 3 Years in Patients with Cystic Fibrosis
  274. DIFFERENCE IN RENAL HANDLING OF CEFSULODIN BETWEEN PATIENTS WITH CYSTIC FIBROSIS AND NORMAL SUBJECTS
  275. Clinical results and pharmacokinetics of ceftazidime treatment in patients with cystic fibrosis
  276. Alpha-1-antitrypsin deficiency and juvenile liver disease Ultrastructural observations compared with light microscopy and routine liver tests
  277. Serum Bile Acids as Markers of Juvenile Liver Disease in α1-Antitrypsin Deficiency
  278. LIVER DISEASE IN CHILDREN WITH ALPHA1-ANTITRYPSIN DEFICIENCY WITHOUT NEONATAL CHOLESTASIS
  279. NATURAL HISTORY OF CHILDREN WITH ALPHA1‐ANTITRYPSIN DEFICIENCY AND NEONATAL CHOLESTASIS
  280. Urinary excretion of bile alcohols in normal children and patients with α1‐antitrypsin deficiency during development of liver disease
  281. RENAL FUNCTION IN CYSTIC FIBROSIS WITH SPECIAL REFERENCE TO THE RENAL SODIUM HANDLING
  282. Tetrahydroxylated bile acids in healthy human newborns
  283. BILE ACID METABOLISM IN LOW BIRTHWEIGHT INFANTS
  284. RENAL DISTURBANCE IN CYSTIC FIBROSIS
  285. THE FIRST INFANT TO SURVIVE A GENERALIZED BCG INFECTION
  286. RENAL FUNCTION IN CYSTIC FIBROSIS
  287. Excretion of bile acids in healthy children and children with cystic fibrosis
  288. Urinary Bile Acid Excretion in Correlation to Liver Histopathology in Cystic Fibrosis
  289. METABOLISM OF LITHOCHOLIC ACID‐24–14C IN EXTRAHEPATIC BILIARY ATRESIA
  290. URINARY BILE ACID CONJUGATES IN EXTRAHEPATIC BILIARY ATRESIA
  291. BILE ACID EXCRETION AFTER DISAPPEARANCE OF JAUNDICE IN INTRAHEPATIC CHOLESTASIS OF INFANCY
  292. EXCRETION OF BILE ACIDS IN EXTRAHEPATIC BILIARY ATRESIA AND INTRAHEPATIC CHOLESTASIS OF INFANCY
  293. EXCRETION OF BILE ACIDS IN ERYTHROBLASTOSIS FOETALIS
  294. BILE ACIDS AND PANCREATIC ENZYMES DURING ABSORPTION IN THE NEWBORN
  295. Excretion of 3β-hydroxy-5-cholenoic and 3a-hydroxy-5a-cholanoic acids in urine of infants with biliary atresia
  296. TEST‐MEAL IN THE DIAGNOSIS OF MALABSORPTION IN INFANCY
  297. INTRAVENOUS GLUCOSE TOLERANCE IN OVERWEIGHT NEWBORN INFANTS AND THEIR MOTHERS
  298. BILE ACID EXCRETION AND MALABSORPTION IN INTRAHEPATIC CHOLESTASIS OF INFANCY (“NEONATAL HEPATITIS”)
  299. AMAUROSIS AFTER BROXYQUINOLINE
  300. Hepatobiliary Disease in Cystic Fibrosis